Premium
A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS
Author(s) -
Michot J.M.,
Carpio C.,
Nastoupil L.,
Chavez J.,
Feldman T.,
Ferrari S.,
Morillo D.,
Bachy E.,
Pinto A.,
Kuruvilla J.,
Buchholz T. J.,
Kasibhatla S.,
Carrancio S.,
Guarinos C.,
Wu F.,
Li S.,
Patah P.,
Pourdehnad M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.89_2881
Subject(s) - medicine , rituximab , tolerability , follicular lymphoma , lymphoma , oncology , mantle cell lymphoma , non hodgkin's lymphoma , diffuse large b cell lymphoma , adverse effect